LAUSR

3.2 0.9, and 1.0 1.3 after 12 months of follow-up, that is an average reduction of more than 2 pressure-lowering eye drops after one year. Sixty-seven per cent of eyes did not need pressure-lowering eye drops one year after surgery. We did not find any statistically significant differences regarding IOP in eyes in which XEN stent implantation was combined with phacoemulsification, except after 1 month (p < 0.01), where IOP was higher in the combined group. The number of eyes included was too small to make any reliable conclusions regarding SLT, but there was a trend (p = 0.05) towards a difference in number of pressure-lowering eye drops after 12 months in favour of those who had not received SLT treatment. Seventy per cent of all eyes did not require any postoperative surgical interventions. Needling (22%) and choroidal effusion (15%) were the most common postoperative surgical procedure and postoperative complication, respectively. Also, one very severe complication, necrotizing scleritis, was noted in this cohort, but after months of antibiotics, steroids and surgery, the eye was saved, and visual acuity and MD had not deteriorated. Seven of our 27 patients had XEN implantation in both of their eyes. When including these eyes in the statistical analyses, the results were largely the same. We therefore conclude that XEN stent implantation is an efficient method to lower IOP and reduce the need for pressure-lowering eye drops in patients with glaucoma for at least 12 months. Most complications in this retrospective study were minor; however, one severe complication was reported. Patients should be informed that reoperation or revision is not unusual. Major limitations to this studywere the relatively low number of patients included and short follow-up time.